Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
71.71
USD
|
+0.27%
|
|
+5.61%
|
-9.90%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,805
|
3,042
|
1,424
|
3,349
|
3,766
|
3,406
|
-
|
-
|
Enterprise Value (EV)
1 |
3,605
|
2,907
|
1,387
|
3,243
|
3,558
|
3,321
|
3,253
|
2,779
|
P/E ratio
|
-51.4
x
|
-29.4
x
|
-10.9
x
|
-16.8
x
|
-15.1
x
|
-18.7
x
|
72.8
x
|
10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
66.9
x
|
13.9
x
|
9.05
x
|
4.97
x
|
3.12
x
|
EV / Revenue
|
-
|
-
|
-
|
64.8
x
|
13.1
x
|
8.82
x
|
4.75
x
|
2.54
x
|
EV / EBITDA
|
-
|
-29.3
x
|
-11.1
x
|
-18.5
x
|
-15.8
x
|
-22.1
x
|
34.3
x
|
7.06
x
|
EV / FCF
|
-77.7
x
|
-37
x
|
-12.8
x
|
-27.7
x
|
-24.4
x
|
-21.5
x
|
-236
x
|
13
x
|
FCF Yield
|
-1.29%
|
-2.7%
|
-7.83%
|
-3.61%
|
-4.09%
|
-4.66%
|
-0.42%
|
7.71%
|
Price to Book
|
21.4
x
|
26.8
x
|
90.9
x
|
30.6
x
|
19.7
x
|
56.2
x
|
17
x
|
4.95
x
|
Nbr of stocks (in thousands)
|
36,809
|
37,344
|
37,692
|
43,426
|
47,320
|
47,493
|
-
|
-
|
Reference price
2 |
103.4
|
81.47
|
37.78
|
77.13
|
79.59
|
71.71
|
71.71
|
71.71
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
2/27/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
50.04
|
270.6
|
376.4
|
685.4
|
1,093
|
EBITDA
1 |
-
|
-99.12
|
-124.6
|
-175.4
|
-225
|
-150.5
|
94.92
|
393.6
|
EBIT
1 |
-67.25
|
-99.14
|
-124.7
|
-179.8
|
-231.8
|
-165.7
|
76.47
|
407.8
|
Operating Margin
|
-
|
-
|
-
|
-359.33%
|
-85.67%
|
-44.03%
|
11.16%
|
37.31%
|
Earnings before Tax (EBT)
1 |
-68.48
|
-101.7
|
-130.4
|
-187.1
|
-238.3
|
-173.4
|
101.2
|
460.7
|
Net income
1 |
-68.35
|
-102.9
|
-130.4
|
-187.1
|
-239.2
|
-183.3
|
53.8
|
367.9
|
Net margin
|
-
|
-
|
-
|
-373.99%
|
-88.41%
|
-48.7%
|
7.85%
|
33.66%
|
EPS
2 |
-2.010
|
-2.770
|
-3.470
|
-4.600
|
-5.270
|
-3.831
|
0.9853
|
7.030
|
Free Cash Flow
1 |
-46.39
|
-78.5
|
-108.5
|
-117.2
|
-145.7
|
-154.6
|
-13.76
|
214.1
|
FCF margin
|
-
|
-
|
-
|
-234.25%
|
-53.83%
|
-41.07%
|
-2.01%
|
19.59%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
54.41%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
58.21%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
2/27/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
8.82
|
16.85
|
24.37
|
94.58
|
46.7
|
57.79
|
71.53
|
73.04
|
87.63
|
101.1
|
117.9
|
110.4
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-40.77
|
-58.22
|
-
|
-
|
-
|
-96.53
|
-60.11
|
-55.23
|
-48.68
|
-43.5
|
-
|
EBIT
1 |
-33.41
|
-32.61
|
-38.29
|
-39.18
|
-42.45
|
-59.92
|
-6.374
|
-65.06
|
-62.12
|
-98.27
|
-55.37
|
-46.02
|
-36.56
|
-24.07
|
-28
|
Operating Margin
|
-
|
-
|
-
|
-444.24%
|
-252.02%
|
-245.85%
|
-6.74%
|
-139.31%
|
-107.49%
|
-137.39%
|
-75.81%
|
-52.52%
|
-36.17%
|
-20.42%
|
-25.37%
|
Earnings before Tax (EBT)
1 |
-34.88
|
-33.98
|
-39.63
|
-41.44
|
-44.82
|
-61.24
|
-8.638
|
-67.79
|
-62.88
|
-98.98
|
-56.59
|
-45.83
|
-35.61
|
-22.28
|
-24.7
|
Net income
1 |
-34.88
|
-33.98
|
-39.63
|
-41.44
|
-44.82
|
-61.24
|
-11.22
|
-67.17
|
-62.2
|
-98.65
|
-58.04
|
-47.55
|
-37.9
|
-26.29
|
-24.7
|
Net margin
|
-
|
-
|
-
|
-469.84%
|
-266.08%
|
-251.28%
|
-11.86%
|
-143.83%
|
-107.62%
|
-137.91%
|
-79.46%
|
-54.27%
|
-37.51%
|
-22.31%
|
-22.37%
|
EPS
2 |
-0.9300
|
-0.9000
|
-1.030
|
-1.060
|
-1.070
|
-1.410
|
-0.2600
|
-1.540
|
-1.320
|
-2.080
|
-1.219
|
-1.014
|
-0.8003
|
-0.5441
|
-0.6600
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
3/1/22
|
5/2/22
|
8/9/22
|
11/7/22
|
2/27/23
|
5/9/23
|
8/7/23
|
11/6/23
|
2/20/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
200
|
136
|
37.4
|
107
|
208
|
84.9
|
153
|
627
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.4
|
-78.5
|
-109
|
-117
|
-146
|
-155
|
-13.8
|
214
|
ROE (net income / shareholders' equity)
|
-
|
-69.5%
|
-202%
|
-299%
|
-159%
|
-139%
|
47.3%
|
87.2%
|
ROA (Net income/ Total Assets)
|
-57.9%
|
-
|
-95.2%
|
-89.3%
|
-
|
-
|
-
|
-
|
Assets
1 |
118
|
-
|
137
|
209.6
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
4.840
|
3.040
|
0.4200
|
2.520
|
4.030
|
1.280
|
4.230
|
14.50
|
Cash Flow per Share
2 |
-
|
-2.110
|
-2.880
|
-2.870
|
-3.190
|
-3.580
|
-
|
-
|
Capex
1 |
0.02
|
0.05
|
0.31
|
0.7
|
0.58
|
1.22
|
1.57
|
2.05
|
Capex / Sales
|
-
|
-
|
-
|
1.4%
|
0.22%
|
0.33%
|
0.23%
|
0.19%
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/1/22
|
2/27/23
|
2/20/24
|
-
|
-
|
-
|
Last Close Price
71.71
USD Average target price
121.1
USD Spread / Average Target +68.91% Consensus |
1st Jan change
|
Capi.
|
---|
| -9.90% | 3.4B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.35B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|